Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C

Keio Journal of Medicine

Volumn 45, Issue 3, 1996, Pages 161-167

  Saito, Hidetsugu ^a   Tsuchimoto, Kanji ^b   Miyaguchi, Shingo ^c   Tada, Shinichiro ^d   Sawaguchi, Kentaro ^e   Komatsu, Kohichi ^f   Kaneko, Kohtaro ^g   Watanabe, Tetsu ^h   Morizane, Toshio ⁱ   Ishii, Hiromasa ^a  

^a KEIO UNIVERSITY   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

^c Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^d NASU RED CROSS HOSPITAL   (Japan)

^e National Hospital Organization   (Japan)

^f National Minami Yokohama Hospital   (Japan)

^g National Hospital Organization Kasumigaura Medical Center   (Japan)

^h TOKAI UNIVERSITY   (Japan)

ⁱ KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

chronic hepatitis C; dose study; interferon; prediction

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; FEVER; HAIR LOSS; HEADACHE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PREDICTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0344532668     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.45.161     Document Type: Article

References (26)

1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis, N Engl J Med 1989; 321: 1494-1500
2. Esteban JI, Gonzalez A, Hernandez JM, Viladomiu L, Sanchcz C, Lopez-Talavera JC, Lucea D, Martin-Vega C, Vidai X. Esteban R, Guardia J, Durako SJ, Alter HJ: Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med 1990; 323: 1107-1112
3. Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcome after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466
4. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG, the National Heart, Lung, Blood Institute Study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-1911
5. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055
6. Omata M, Ito Y, Yokosuka O, Imazeki F, Uchiumi K, Takano S, Hosoda K, Ohto M: Histological changes of the liver by treatment of chronic non-A, non B hepatitis with recombinant leukocyte interferon alpha. Comparison with histological changes in chronic hepatitis B. Dig Dis Sci 1989; 34: 330-337
7. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, the Multiccnter Study Group: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-1462
8. Tsubota A, Chayama K, Ikeda K, Arase Y, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Kumada H: Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094
9. Yasuda K, Koike K, Yotsuyanagi II, Moriya K, Maruyama T, Sugata F, Hino K, Kurokawa K, lino S: One-point quantitative determination of pretreatment serum hepatitis C virus RNA predicts long-term responsiveness to high-dose interferon therapy. Int Hepatol Commun 1995; 3: 144-153
10. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM: Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686-690
11. Kleter GE, Brouwer JT, Heijtink RA, Schalm SW, Quint WG: Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with α interferon. Antimicrob Agents Chemother 1993; 37: 595-597
12. Terrault N, Wright T: Interferon and hepatitis C virus infection. N Engl J Med 1995; 332: 1509-1511
13. Kaneko S, Unoura M, Kobayashi K, Kuno K, Murakami S, Hattori N: Detection of serum hepatitis C virus RNA. Lancet 1990; 335:976
14. Bianchi L, DeGroote J, Desmet VJ, Gdigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Wepler W: Acute and chronic hepatitis revisited. Review by an international group. Lancet 1977; 2: 914-919
15. Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, Machida A, Mishiro S, Yoshizawa H, Miyakawa Y: Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215-222
16. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K: Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524-9528
17. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159
18. Saito H, Ebinuma H, Tada S, Tsunematsu S, Atsukawa K, Masuda T, Tsuchiya M, Ishii H: Enhancing effect of the liver extract and flavin adenin dinucleotide mixture on anti-viral efficacy of interferon in patients with chronic hepatitis C. Keio J Med 1996; 45: 48-53
19. Kagawa T, Morizane T, Saito H, Miyaguchi S, Tsunematsu S, Tada S, Guevara FM, Kumagai N, Tsuchimoto K, Watanabe T, Tsuchiya M: A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol 1993; 17: 91-96
20. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP: Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397
21. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K: A controlled study to determine the optimal dose regimen of interferon-α2b in chronic hepatitis C Am J Gastroenterol 1995; 90: 1246-1249
22. Lindsay KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, Perillo R, Tamburro C, Silva M, Goff C, Everson G, Sanghvi B, Albrecht J: Long-term response to higher doses of interferon (IFN) α-2b treatment of patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1993; 18 (Suppl): 106A
23. Benelux Multicentre Trial Study Group: Benelux multicentre trial of α interferon treatment for chronic hepatitis C: standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Gut 1993; (Suppl): S119-S120
24. lino S, Hino K, Kuroki T, Suzuki H, Yamamoto S: Treatment of chronic hepatitis C with high dose interferon α-2b. Dig Dis Sci 1993; 38: 612-618
25. Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Tagger A, Pollice L, Tremolada F, Davite C, Realdi G, Ruol A: Treatment of chronic hepatitis C with recombinant human interferon-α2a: results of a randomized controlled clinical trial. Hepatology 1994; 19: 1-5
26. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, Yun ZB, Weiland O: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 1994; 19: 280-285